Keros Therapeutics (KROS) said Wednesday that it will repurchase almost 11 million shares at $17.75 each, or a total of $194.4 million, in a tender offer that expired on Tuesday.
The offer was oversubscribed, with about 16.7 million shares validly tendered and about 1.2 million shares tendered through notice of guaranteed delivery, the company said.
The shares to be acquired represent around 35.91% of the company's outstanding stock as of Tuesday, Keros said
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments